<p><strong>Background: </strong>Colorectal peritoneal metastases are associated with poor prognosis. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy may improve survival in selected patients.</p><p><strong>Purpose: </strong>To evaluate survival outcomes and identify prognostic factors affecting overall survival and disease-free survival in patients with colorectal peritoneal metastases undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.</p><p><strong>Design: </strong>Retrospective cohort study.</p><p><strong>Settings: </strong>This study was conducted at a single tertiary referral center between January 2013 and March 2024.</p><p><strong>Patients: </strong>Ninety-two patients with colorectal peritoneal metastases treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy were included. The cohort comprised 52 men and 40 women with a mean age of 46 years. Synchronous metastases were present in 75% of cases.</p><p><strong>Interventions: </strong>All patients underwent cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy.</p><p><strong>Main outcome measures: </strong>Overall survival, disease-free survival, and prognostic factors influencing outcomes were the main outcome measures.</p><p><strong>Results: </strong>Complete cytoreduction was achieved in 92.3% of patients. The median overall survival was 24 months, and the median disease-free survival was 11 months. The 3- and 5-year overall survival rates were 43.6% and 32.2%, respectively. An increased Peritoneal Cancer Index was independently associated with decreased overall survival, with poorer outcomes observed for a Peritoneal Cancer Index greater than 16 (HR 1.06, p = 0.016). The presence of perineural invasion (HR 2.06, p = 0.030) and intraoperative blood loss >1500 mL (HR 1.96, p = 0.018) were also associated with reduced survival. These factors may help stratify patients for optimal surgical outcomes.</p><p><strong>Limitations: </strong>Retrospective design, single-center experience, and limited molecular data may affect generalizability. Longer follow-up is needed to evaluate late recurrences and long-term survival.</p><p><strong>Conclusions: </strong>Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy improves survival in selected patients with colorectal peritoneal metastases. High Peritoneal Cancer Index, perineural invasion, and excessive blood loss predict poorer outcomes and should guide patient selection. See Video Abstract .</p><p><strong>Factores pronsticos y resultados a largo plazo en pacientes con metstasis peritoneales colorrectales tratados con ciruga citorreductora y quimioterapia intraperitoneal hipertrmica un estudio de cohorte retrospectivo de un centro de atencin terciaria en la india: </strong>ANTECEDENTES:Las metástasis peritoneales colorrectales se asocian con un mal pronóstico. La cirugía citorreductora combinada con quimioterapia intraperitoneal hi
{"title":"Prognostic Factors and Long-term Outcomes in Patients With Colorectal Peritoneal Metastases Treated With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Retrospective Cohort Study From a Tertiary Care Center in India.","authors":"Manisha Aggarwal, Abhishek Aggarwal, Shaifali Goel, Sumit Goyal, Prerna Garg, Gurudutt Gupta, Shivendra Singh","doi":"10.1097/DCR.0000000000003995","DOIUrl":"10.1097/DCR.0000000000003995","url":null,"abstract":"<p><strong>Background: </strong>Colorectal peritoneal metastases are associated with poor prognosis. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy may improve survival in selected patients.</p><p><strong>Purpose: </strong>To evaluate survival outcomes and identify prognostic factors affecting overall survival and disease-free survival in patients with colorectal peritoneal metastases undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.</p><p><strong>Design: </strong>Retrospective cohort study.</p><p><strong>Settings: </strong>This study was conducted at a single tertiary referral center between January 2013 and March 2024.</p><p><strong>Patients: </strong>Ninety-two patients with colorectal peritoneal metastases treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy were included. The cohort comprised 52 men and 40 women with a mean age of 46 years. Synchronous metastases were present in 75% of cases.</p><p><strong>Interventions: </strong>All patients underwent cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy.</p><p><strong>Main outcome measures: </strong>Overall survival, disease-free survival, and prognostic factors influencing outcomes were the main outcome measures.</p><p><strong>Results: </strong>Complete cytoreduction was achieved in 92.3% of patients. The median overall survival was 24 months, and the median disease-free survival was 11 months. The 3- and 5-year overall survival rates were 43.6% and 32.2%, respectively. An increased Peritoneal Cancer Index was independently associated with decreased overall survival, with poorer outcomes observed for a Peritoneal Cancer Index greater than 16 (HR 1.06, p = 0.016). The presence of perineural invasion (HR 2.06, p = 0.030) and intraoperative blood loss >1500 mL (HR 1.96, p = 0.018) were also associated with reduced survival. These factors may help stratify patients for optimal surgical outcomes.</p><p><strong>Limitations: </strong>Retrospective design, single-center experience, and limited molecular data may affect generalizability. Longer follow-up is needed to evaluate late recurrences and long-term survival.</p><p><strong>Conclusions: </strong>Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy improves survival in selected patients with colorectal peritoneal metastases. High Peritoneal Cancer Index, perineural invasion, and excessive blood loss predict poorer outcomes and should guide patient selection. See Video Abstract .</p><p><strong>Factores pronsticos y resultados a largo plazo en pacientes con metstasis peritoneales colorrectales tratados con ciruga citorreductora y quimioterapia intraperitoneal hipertrmica un estudio de cohorte retrospectivo de un centro de atencin terciaria en la india: </strong>ANTECEDENTES:Las metástasis peritoneales colorrectales se asocian con un mal pronóstico. La cirugía citorreductora combinada con quimioterapia intraperitoneal hi","PeriodicalId":11299,"journal":{"name":"Diseases of the Colon & Rectum","volume":" ","pages":"42-52"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145354145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-10-20DOI: 10.1097/DCR.0000000000003992
Yeqian Huang, Cherry E Koh
{"title":"Diagnosis and Management of Rectoceles.","authors":"Yeqian Huang, Cherry E Koh","doi":"10.1097/DCR.0000000000003992","DOIUrl":"10.1097/DCR.0000000000003992","url":null,"abstract":"","PeriodicalId":11299,"journal":{"name":"Diseases of the Colon & Rectum","volume":" ","pages":"4-8"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145328480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-10-06DOI: 10.1097/DCR.0000000000003807
Yogesh Bansod, Ashwin L Desouza, Avanish Saklani
{"title":"Medial Psoas Space Approach for Robotic En Bloc Pelvic Lymph Node Dissection for Anal Canal Melanoma.","authors":"Yogesh Bansod, Ashwin L Desouza, Avanish Saklani","doi":"10.1097/DCR.0000000000003807","DOIUrl":"10.1097/DCR.0000000000003807","url":null,"abstract":"","PeriodicalId":11299,"journal":{"name":"Diseases of the Colon & Rectum","volume":" ","pages":"102-103"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145238051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-10-24DOI: 10.1097/DCR.0000000000003987
Laura M Fernandez, José Moreira Azevedo, Ines Santiago, Mireia Castillo-Martin, Barbara Cardoso, Carlos T Carvalho, Richard J Heald, Amjad Parvaiz
<p><strong>Background: </strong>Rectal cancer management has evolved, with neoadjuvant chemoradiotherapy accepted as the criterion standard for locally advanced tumors, reducing local recurrence but at the cost of the detrimental effects of radiation. In addition, neoadjuvant therapy has failed to improve survival. Total neoadjuvant therapy may lower metastasis rates but increase toxicity. Currently, most international guidelines recommend routine use of total neoadjuvant therapy for stage II/III rectal cancer.Magnetic resonance staging may be used to identify patients at low risk for local recurrence after high-quality total mesorectal surgery and selective adjuvant chemotherapy.</p><p><strong>Objective: </strong>Analyze oncological outcomes in patients with stage II and III rectal cancer selected for upfront surgery based on refined magnetic resonance criteria.</p><p><strong>Design: </strong>Retrospective analysis of a prospective database.</p><p><strong>Settings: </strong>Patients with rectal cancer from a single tertiary institution undergoing upfront resection between September 2013 and May 2024.</p><p><strong>Patients: </strong>Patients had clinical stage II/III rectal cancer (mrT3/T4 and/or mrN + tumors) with clear mesorectal fascia (>1 mm). The hypothesis was that in selected patients who would otherwise be candidates for routine total neoadjuvant therapy based on international guidelines, upfront surgery may achieve excellent local disease control, thereby minimizing the benefits of preoperative radiation therapy or chemotherapy.</p><p><strong>Main outcome measures: </strong>Local recurrence-free survival, negative resection margin, and distant metastasis-free survival were the main outcome measures.</p><p><strong>Results: </strong>Among 322 patients, 141 underwent upfront surgery, 94 of whom harbored stage II/III rectal cancer and constituted the population of our study. The median distance of the tumor to the anorectal ring was 47 mm. R0 was achieved in 99%. Local recurrence-free survival at 3 years was 100% and at 5 years was 97%. Three-year and 5-year distant metastasis-free survival were 87% and 81%, respectively. Overall survival at 3 and 5 years was 97% and 95%, with a median follow-up of 34.5 months.</p><p><strong>Limitations: </strong>Retrospective analysis, single-center data.</p><p><strong>Conclusions: </strong>Patients who underwent upfront surgery with high-quality total mesorectal excision as identified by high-resolution MRI achieved excellent oncological outcomes, making neoadjuvant therapy unnecessary in a subset of stage II/III rectal cancers with clear mesorectal fascia. See Video Abstract .</p><p><strong>Una proporcin significativa de cnceres rectales en estadio ii y iii, seleccionados mediante resonancia magntica de precisin, pueden tratarse de forma segura mediante ciruga de extirpacin mesorrectal total inicial sin terapia neoadyuvante: </strong>ANTECEDENTES:El tratamiento del cáncer rectal ha evolucionado, y la qui
{"title":"A Significant Proportion of Stage II and III Rectal Cancers, Selected by Precision Magnetic Resonance, Can Safely Be Managed by Upfront Total Mesorectal Excision Surgery Without Neoadjuvant Therapy.","authors":"Laura M Fernandez, José Moreira Azevedo, Ines Santiago, Mireia Castillo-Martin, Barbara Cardoso, Carlos T Carvalho, Richard J Heald, Amjad Parvaiz","doi":"10.1097/DCR.0000000000003987","DOIUrl":"10.1097/DCR.0000000000003987","url":null,"abstract":"<p><strong>Background: </strong>Rectal cancer management has evolved, with neoadjuvant chemoradiotherapy accepted as the criterion standard for locally advanced tumors, reducing local recurrence but at the cost of the detrimental effects of radiation. In addition, neoadjuvant therapy has failed to improve survival. Total neoadjuvant therapy may lower metastasis rates but increase toxicity. Currently, most international guidelines recommend routine use of total neoadjuvant therapy for stage II/III rectal cancer.Magnetic resonance staging may be used to identify patients at low risk for local recurrence after high-quality total mesorectal surgery and selective adjuvant chemotherapy.</p><p><strong>Objective: </strong>Analyze oncological outcomes in patients with stage II and III rectal cancer selected for upfront surgery based on refined magnetic resonance criteria.</p><p><strong>Design: </strong>Retrospective analysis of a prospective database.</p><p><strong>Settings: </strong>Patients with rectal cancer from a single tertiary institution undergoing upfront resection between September 2013 and May 2024.</p><p><strong>Patients: </strong>Patients had clinical stage II/III rectal cancer (mrT3/T4 and/or mrN + tumors) with clear mesorectal fascia (>1 mm). The hypothesis was that in selected patients who would otherwise be candidates for routine total neoadjuvant therapy based on international guidelines, upfront surgery may achieve excellent local disease control, thereby minimizing the benefits of preoperative radiation therapy or chemotherapy.</p><p><strong>Main outcome measures: </strong>Local recurrence-free survival, negative resection margin, and distant metastasis-free survival were the main outcome measures.</p><p><strong>Results: </strong>Among 322 patients, 141 underwent upfront surgery, 94 of whom harbored stage II/III rectal cancer and constituted the population of our study. The median distance of the tumor to the anorectal ring was 47 mm. R0 was achieved in 99%. Local recurrence-free survival at 3 years was 100% and at 5 years was 97%. Three-year and 5-year distant metastasis-free survival were 87% and 81%, respectively. Overall survival at 3 and 5 years was 97% and 95%, with a median follow-up of 34.5 months.</p><p><strong>Limitations: </strong>Retrospective analysis, single-center data.</p><p><strong>Conclusions: </strong>Patients who underwent upfront surgery with high-quality total mesorectal excision as identified by high-resolution MRI achieved excellent oncological outcomes, making neoadjuvant therapy unnecessary in a subset of stage II/III rectal cancers with clear mesorectal fascia. See Video Abstract .</p><p><strong>Una proporcin significativa de cnceres rectales en estadio ii y iii, seleccionados mediante resonancia magntica de precisin, pueden tratarse de forma segura mediante ciruga de extirpacin mesorrectal total inicial sin terapia neoadyuvante: </strong>ANTECEDENTES:El tratamiento del cáncer rectal ha evolucionado, y la qui","PeriodicalId":11299,"journal":{"name":"Diseases of the Colon & Rectum","volume":" ","pages":"15-23"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145354143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-12-23DOI: 10.1097/DCR.0000000000004068
{"title":"January 2026 Translations.","authors":"","doi":"10.1097/DCR.0000000000004068","DOIUrl":"https://doi.org/10.1097/DCR.0000000000004068","url":null,"abstract":"","PeriodicalId":11299,"journal":{"name":"Diseases of the Colon & Rectum","volume":"69 1","pages":"111-150"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145809790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-10-24DOI: 10.1097/DCR.0000000000003994
Isabel Snee, Sami Ferdousian, Rachel N Rohrich, Ryan P Lin, Christian X Lava, Anusha Singh, Ilana G Margulies, Kenneth L Fan, David M Lisle, Gabriel A Del Corral
<p><strong>Background: </strong>Sigmoid colon vaginoplasty is a gender-affirming procedure offering a self-lubricating neovagina with adequate depth. However, the impact of BMI on outcomes of sigmoid colon vaginoplasty remains unclear.</p><p><strong>Objective: </strong>To evaluate the effect of elevated BMI on short- and medium-term postoperative outcomes in patients undergoing sigmoid colon vaginoplasty.</p><p><strong>Design: </strong>Retrospective cohort study.</p><p><strong>Setting: </strong>Single-institution study conducted at a tertiary academic medical center.</p><p><strong>Patients: </strong>Transgender and nonbinary patients who underwent sigmoid colon vaginoplasty between December 2020 and February 2024 with a minimum of 6 months postoperative follow-up. Patients were stratified into BMI ≥35 (obese) and BMI <35 (nonobese) cohorts.</p><p><strong>Interventions: </strong>Sigmoid colon vaginoplasty, performed by senior surgeons using robotic-assisted techniques. No additional interventions were tested.</p><p><strong>Main outcome measures: </strong>Operative time, length of stay, time to mobilization and dilation, short- and medium-term postoperative complications, reoperation, and revision rates.</p><p><strong>Results: </strong>A total of 119 patients (median age 33 years) were included, with 29 (24.4%) classified as obese. Obese patients had significantly higher BMI (37.3 vs 26.7, p < 0.001) and were more likely to have ASA III classification (20.7% vs 4.4%, p = 0.006). There were no significant differences in operative time (203 vs 188.5 min, p = 0.277), hospital stay, or mobilization. Patients with BMI ≥35 had higher but nonsignificant rates of short-term complications (24.1% vs 15.6%, p = 0.292), including bowel injury and dehiscence. Medium-term complications, such as vaginal prolapse, stenosis, reoperation, and revision vaginoplasty, were similar between groups.</p><p><strong>Limitations: </strong>Single-center retrospective design with a limited obese patient sample size and absence of long-term functional outcomes.</p><p><strong>Conclusions: </strong>Although differences were not statistically significant, patients with BMI ≥35 demonstrated higher complication rates, suggesting a potential trend that warrants further investigation. Sigmoid colon vaginoplasty appears safe in appropriately selected patients across BMI categories, but individualized risk assessment and close perioperative monitoring are advised, particularly in patients with higher BMIs. See Video Abstract .</p><p><strong>Ms all del lmite resultados tras la vaginoplastia sigmoidea en pacientes con un imc: </strong>ANTECEDENTES:La vaginoplastia con colon sigmoide es un procedimiento de reafirmación de género que ofrece una neovagina autolubricante con la profundidad adecuada. Sin embargo, el impacto del IMC en los resultados de la vaginoplastia con colon sigmoide sigue sin estar claro.OBJETIVO:Evaluar el efecto del IMC elevado en los resultados posoperatorios a corto y
背景：乙状结肠阴道成形术是一种性别确认手术，提供具有足够深度的自润滑新阴道。然而，BMI对乙状结肠阴道成形术结果的影响尚不清楚。目的：探讨BMI升高对乙状结肠阴道成形术患者术后中短期预后的影响。设计：回顾性队列研究。环境：在三级学术医疗中心进行的单机构研究。患者：在2020年12月至2024年2月期间接受乙状结肠阴道成形术的变性和非二元患者，术后随访至少6个月。患者被分为BMI≥35 kg/m2（肥胖）和BMI干预：由高级外科医生使用机器人辅助技术进行乙状结肠阴道成形术。没有测试其他干预措施。主要观察指标：手术时间、住院时间、活动和扩张时间、术后中短期并发症、再手术和翻修率。结果：共纳入119例患者（中位年龄33岁），其中29例（24.4%）为肥胖。肥胖患者的BMI （37.3 vs. 26.7, p < 0.001）和ASA III级（20.7% vs. 4.4%, p = 0.006）明显高于肥胖患者。两组在手术时间（203 vs. 188.5 min, p = 0.277）、住院时间和活动量方面均无显著差异。BMI≥35的患者有更高但不显著的短期并发症发生率（24.1%比15.6%,p = 0.292），包括肠损伤和裂孔。中期并发症，如阴道脱垂、狭窄、再手术和阴道翻修成形术，两组间相似。局限性：单中心回顾性设计，肥胖患者样本量有限，缺乏长期功能结果。结论：虽然差异无统计学意义，但BMI≥35的患者并发症发生率较高，提示有进一步研究的潜在趋势。乙状结肠阴道成形术在适当选择的不同BMI类别的患者中是安全的，但建议个体化风险评估和严密的围手术期监测，特别是在高BMI个体中。参见视频摘要。
{"title":"Beyond the Cutoff: Outcomes After Sigmoid Colon Vaginoplasty in Patients With BMI ≥35.","authors":"Isabel Snee, Sami Ferdousian, Rachel N Rohrich, Ryan P Lin, Christian X Lava, Anusha Singh, Ilana G Margulies, Kenneth L Fan, David M Lisle, Gabriel A Del Corral","doi":"10.1097/DCR.0000000000003994","DOIUrl":"10.1097/DCR.0000000000003994","url":null,"abstract":"<p><strong>Background: </strong>Sigmoid colon vaginoplasty is a gender-affirming procedure offering a self-lubricating neovagina with adequate depth. However, the impact of BMI on outcomes of sigmoid colon vaginoplasty remains unclear.</p><p><strong>Objective: </strong>To evaluate the effect of elevated BMI on short- and medium-term postoperative outcomes in patients undergoing sigmoid colon vaginoplasty.</p><p><strong>Design: </strong>Retrospective cohort study.</p><p><strong>Setting: </strong>Single-institution study conducted at a tertiary academic medical center.</p><p><strong>Patients: </strong>Transgender and nonbinary patients who underwent sigmoid colon vaginoplasty between December 2020 and February 2024 with a minimum of 6 months postoperative follow-up. Patients were stratified into BMI ≥35 (obese) and BMI <35 (nonobese) cohorts.</p><p><strong>Interventions: </strong>Sigmoid colon vaginoplasty, performed by senior surgeons using robotic-assisted techniques. No additional interventions were tested.</p><p><strong>Main outcome measures: </strong>Operative time, length of stay, time to mobilization and dilation, short- and medium-term postoperative complications, reoperation, and revision rates.</p><p><strong>Results: </strong>A total of 119 patients (median age 33 years) were included, with 29 (24.4%) classified as obese. Obese patients had significantly higher BMI (37.3 vs 26.7, p < 0.001) and were more likely to have ASA III classification (20.7% vs 4.4%, p = 0.006). There were no significant differences in operative time (203 vs 188.5 min, p = 0.277), hospital stay, or mobilization. Patients with BMI ≥35 had higher but nonsignificant rates of short-term complications (24.1% vs 15.6%, p = 0.292), including bowel injury and dehiscence. Medium-term complications, such as vaginal prolapse, stenosis, reoperation, and revision vaginoplasty, were similar between groups.</p><p><strong>Limitations: </strong>Single-center retrospective design with a limited obese patient sample size and absence of long-term functional outcomes.</p><p><strong>Conclusions: </strong>Although differences were not statistically significant, patients with BMI ≥35 demonstrated higher complication rates, suggesting a potential trend that warrants further investigation. Sigmoid colon vaginoplasty appears safe in appropriately selected patients across BMI categories, but individualized risk assessment and close perioperative monitoring are advised, particularly in patients with higher BMIs. See Video Abstract .</p><p><strong>Ms all del lmite resultados tras la vaginoplastia sigmoidea en pacientes con un imc: </strong>ANTECEDENTES:La vaginoplastia con colon sigmoide es un procedimiento de reafirmación de género que ofrece una neovagina autolubricante con la profundidad adecuada. Sin embargo, el impacto del IMC en los resultados de la vaginoplastia con colon sigmoide sigue sin estar claro.OBJETIVO:Evaluar el efecto del IMC elevado en los resultados posoperatorios a corto y ","PeriodicalId":11299,"journal":{"name":"Diseases of the Colon & Rectum","volume":" ","pages":"87-94"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145354144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-10-29DOI: 10.1097/DCR.0000000000003880
Noelia Ibáñez, Quiteria Hernández, Jesús Abrisqueta, Israel Abellán, Mariano J Montoya, Gines García Buendía, Juan de Dios García, Pablo Ramírez
{"title":"New Scenarios in Coloproctology: Colovaginoplasty With Sigmoid Flap After Rectoneovaginal Fistula in Transgender Patient.","authors":"Noelia Ibáñez, Quiteria Hernández, Jesús Abrisqueta, Israel Abellán, Mariano J Montoya, Gines García Buendía, Juan de Dios García, Pablo Ramírez","doi":"10.1097/DCR.0000000000003880","DOIUrl":"https://doi.org/10.1097/DCR.0000000000003880","url":null,"abstract":"","PeriodicalId":11299,"journal":{"name":"Diseases of the Colon & Rectum","volume":"69 1","pages":"100-101"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145809793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-11-04DOI: 10.1097/DCR.0000000000004013
Yihan Xu, Tianrun Song, Lei Cao, Yi Li, Weiming Zhu, Jianfeng Gong, Zekuan Xu, Zhen Guo
<p><strong>Background: </strong>Sarcopenic obesity is associated with poor prognosis in many diseases, but its role in postoperative complications in IBD remains unclear.</p><p><strong>Objective: </strong>To investigate the association of sarcopenic obesity with major complication risk in patients with IBD who underwent bowel resection surgery.</p><p><strong>Design: </strong>Retrospective cohort analysis.</p><p><strong>Settings: </strong>Single tertiary care center.</p><p><strong>Patients: </strong>Patients with IBD who underwent abdominal surgery between January 2019 and December 2023 were included. Skeletal muscle mass and visceral adipose tissue were evaluated by preoperative CT at the level of the third lumbar vertebra (L3) to define sarcopenia and obesity. Patients were classified into 1 of 4 body composition groups according to the presence or absence of sarcopenia and obesity.</p><p><strong>Main outcome measures: </strong>Major postoperative complications within 30 days.</p><p><strong>Results: </strong>A total of 274 patients were included. Body composition was classified as sarcopenic nonobesity in 121 patients (44.2%), nonsarcopenic nonobesity in 85 patients (31.0%), nonsarcopenic obesity in 34 patients (12.4%), and sarcopenic obesity in 34 patients (12.4%). A similar percentage of minor complications occurred in the 4 groups. However, patients with sarcopenic obesity had a significantly greater rate of major complications (52.9%) than those with nonsarcopenic obesity (28.1%), sarcopenic nonobesity (20.6%), and nonsarcopenic nonobesity (8.2%, p < 0.001). Multivariate analysis identified sarcopenic obesity as a significant risk factor for major complications (OR 14.10; 95% CI, 3.02-65.8; p < 0.001) in patients with IBD undergoing bowel resection surgery. In addition, current smokers, a change in the level of C-reactive protein (postoperative day 5 - postoperative day 1) >0 mg/L, preoperative enteral nutrition therapy, and a preoperative albumin level >35 g/L were also confirmed as independent risk factors for major complications. Moreover, nomogram models were constructed for patients with Crohn's disease and patients with ulcerative colitis to better predict the risk of major complications.</p><p><strong>Limitations: </strong>This was a single-center retrospective study.</p><p><strong>Conclusions: </strong>Sarcopenic obesity was identified as a significant risk factor for major complications in patients with IBD undergoing bowel resection surgery. See Video Abstract .</p><p><strong>Impacto de la obesidad sarcopnica en los resultados posoperatorios de pacientes con enfermedad inflamatoria intestinal sometidos a ciruga de reseccin intestinal un estudio de cohorte retrospectivo: </strong>ANTECEDENTES:La obesidad sarcopénica se asocia con un mal pronóstico en muchas enfermedades, pero su papel en las complicaciones posoperatorias en la EII sigue sin estar claro.OBJETIVO:Investigar la asociación de la obesidad sarcopénica con el riesgo de com
{"title":"Impact of Sarcopenic Obesity on Postoperative Outcomes in Patients With IBD After Bowel Resection Surgery: A Retrospective Cohort Study.","authors":"Yihan Xu, Tianrun Song, Lei Cao, Yi Li, Weiming Zhu, Jianfeng Gong, Zekuan Xu, Zhen Guo","doi":"10.1097/DCR.0000000000004013","DOIUrl":"10.1097/DCR.0000000000004013","url":null,"abstract":"<p><strong>Background: </strong>Sarcopenic obesity is associated with poor prognosis in many diseases, but its role in postoperative complications in IBD remains unclear.</p><p><strong>Objective: </strong>To investigate the association of sarcopenic obesity with major complication risk in patients with IBD who underwent bowel resection surgery.</p><p><strong>Design: </strong>Retrospective cohort analysis.</p><p><strong>Settings: </strong>Single tertiary care center.</p><p><strong>Patients: </strong>Patients with IBD who underwent abdominal surgery between January 2019 and December 2023 were included. Skeletal muscle mass and visceral adipose tissue were evaluated by preoperative CT at the level of the third lumbar vertebra (L3) to define sarcopenia and obesity. Patients were classified into 1 of 4 body composition groups according to the presence or absence of sarcopenia and obesity.</p><p><strong>Main outcome measures: </strong>Major postoperative complications within 30 days.</p><p><strong>Results: </strong>A total of 274 patients were included. Body composition was classified as sarcopenic nonobesity in 121 patients (44.2%), nonsarcopenic nonobesity in 85 patients (31.0%), nonsarcopenic obesity in 34 patients (12.4%), and sarcopenic obesity in 34 patients (12.4%). A similar percentage of minor complications occurred in the 4 groups. However, patients with sarcopenic obesity had a significantly greater rate of major complications (52.9%) than those with nonsarcopenic obesity (28.1%), sarcopenic nonobesity (20.6%), and nonsarcopenic nonobesity (8.2%, p < 0.001). Multivariate analysis identified sarcopenic obesity as a significant risk factor for major complications (OR 14.10; 95% CI, 3.02-65.8; p < 0.001) in patients with IBD undergoing bowel resection surgery. In addition, current smokers, a change in the level of C-reactive protein (postoperative day 5 - postoperative day 1) >0 mg/L, preoperative enteral nutrition therapy, and a preoperative albumin level >35 g/L were also confirmed as independent risk factors for major complications. Moreover, nomogram models were constructed for patients with Crohn's disease and patients with ulcerative colitis to better predict the risk of major complications.</p><p><strong>Limitations: </strong>This was a single-center retrospective study.</p><p><strong>Conclusions: </strong>Sarcopenic obesity was identified as a significant risk factor for major complications in patients with IBD undergoing bowel resection surgery. See Video Abstract .</p><p><strong>Impacto de la obesidad sarcopnica en los resultados posoperatorios de pacientes con enfermedad inflamatoria intestinal sometidos a ciruga de reseccin intestinal un estudio de cohorte retrospectivo: </strong>ANTECEDENTES:La obesidad sarcopénica se asocia con un mal pronóstico en muchas enfermedades, pero su papel en las complicaciones posoperatorias en la EII sigue sin estar claro.OBJETIVO:Investigar la asociación de la obesidad sarcopénica con el riesgo de com","PeriodicalId":11299,"journal":{"name":"Diseases of the Colon & Rectum","volume":" ","pages":"53-63"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145437858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-10-06DOI: 10.1097/DCR.0000000000003791
Fred C Kobylarz, Salvatore A Parascandola, Aimal Khan
{"title":"Right Colectomy Using Single-Port Robotic Platform.","authors":"Fred C Kobylarz, Salvatore A Parascandola, Aimal Khan","doi":"10.1097/DCR.0000000000003791","DOIUrl":"10.1097/DCR.0000000000003791","url":null,"abstract":"","PeriodicalId":11299,"journal":{"name":"Diseases of the Colon & Rectum","volume":" ","pages":"104"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145238076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：